; (2) work with law enforcement agencies and public health authorities, as practicable, to develop real-time information on the purity and movement of fentanyl, its analogues, and other synthetic opioids; (3) assist State and local law enforcement agencies in testing seized drugs when State and local forensic laboratories request additional assistance; (4) provide early warning information and advice to Federal, State, and local law enforcement agencies and public health authorities of potential significant changes in the supply of fentanyl, its analogues, and other synthetic opioids; (5) provide biosurveillance for non-fatal exposures to fentanyl, fentanyl analogues, and other synthetic opioids; and (6) provide diagnostic testing for such non-fatal exposures to emergency personnel. (d) Authorization of appropriations To carry out this section, there is authorized to be appropriated $15,000,000 for each of fiscal years 2019 through 2023. 3. Enhanced fentanyl surveillance (a) In general The Director of the Centers for Disease Control and Prevention shall enhance its drug surveillance program by— (1) expanding its surveillance program to include all 50 States and the territories of the United States; (2) increasing and accelerating the collection of data on fentanyl, its analogues, other synthetic opioids, and new emerging drugs of abuse, including related overdose data from medical examiners and drug treatment admissions; and (3) utilizing available and emerging information on fentanyl, its analogues, other synthetic opioids, and new emerging drugs of abuse, including information from— (A) the National Drug Early Warning System; (B) State and local public health authorities; and (C) Federal, State, and local public health laboratories. (b) Authorization of appropriations To carry out this section, there is authorized to be appropriated $10,000,000 for each of fiscal years 2019 through 2023.